Full Press Release Details
PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June.
Presentation details are outlined below.
American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting
Invited Oral Presentation
Title: HSV-1 as a vector system for targeting respiratory tissues in genetic pulmonary disease
Presenter: Trevor Parry, PhD
Date and Time: May 17, 2025 at 8:50AM CT
2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Title: Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study
Presenter: Wen Wee Ma, MD, Enterprise Vice Chair, Research, Cancer Institute, Cleveland Clinic
Date and Time: June 2, 2025 from 1:30PM to 4:30PM CT
Poster Session or Category: Developmental Therapeutics – Immunotherapy
Abstract Number: 2575
Poster Bd Number: 222
Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Title: Topical application of the HSV-1-based gene therapy vector KB801 results in sustained nerve growth factor expression in wounded murine corneas
Presenter: Haley Cartwright, PhD
Date and Time: May 5, 2025 from 3:00PM to 4:45PM MT
Poster Session or Category: 258 – Preclinical Therapeutics
Poster Number: B0154
Society for Investigative Dermatology (SID) 2025 Annual Meeting
Title: Expansion of an HSV-1-based gene therapy platform to treat Hailey-Hailey and Darier diseases
Presenter: Bruce Nmezi, PhD
Date and Time: May 9, 2025 from 4:30PM to 6:00PM PT
Poster Session or Category: Genetic Disease, Gene Regulation, Gene Therapy & Epigenetics
Additional presentation details will be available to conference attendees. Following completion of each conference, presentation slides or posters, as applicable, will also be available to view online on the Investor section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
Investors and Media:
Stéphane Paquette, PhD